Stocks Health care IRMD
NASDAQ · Health careIradimed Corp (IRMD)
Iradimed Corp brought in $89.3M of revenue over the twelve months to September 30, 2026, up 11.0% from a year earlier. Net income was $24M, a net margin of 26.8%. Operating cash flow minus capital spending left $17.2M of free cash flow in fiscal 2025. At September 30, 2026 it held $63.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 30, 2026.
Key facts about Iradimed Corp
- Net worth
- Iradimed Corp has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $106.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $83.8M (+14.4% year on year), with net income of $22.5M. Over the 12 months to September 30, 2026: revenue $89.3M, net income $24M.
- Cash flow
- In fiscal 2025 operations brought in $24.9M of cash; after $7.8M of capital spending, free cash flow was $17.2M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 30, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Iradimed Corp's next report is expected around February 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Iradimed Corp does
Iradimed Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker IRMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $83.8M | $22.5M | $1.75 | $17.2M |
| 2024 | $73.2M | $19.2M | $1.50 | $17.6M |
| 2023 | $65.6M | $17.2M | $1.35 | $6M |
| 2022 | $53.3M | $12.8M | $1.02 | $9.2M |
| 2021 | $41.8M | $9.3M | $0.74 | $10.8M |
| 2020 | $31.7M | $1.4M | $0.11 | $5.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IRMD ranks in Health care
Dividends
It paid out $15M in cash dividends, 67% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $15M | 67% |
| 2024 | n/a | $13.7M | 71% |
| 2023 | n/a | $13.2M | 77% |
| 2022 | n/a | $12.6M | 98% |
Latest SEC filings
What Iradimed Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 30, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 14% to $24.2M versus the same quarter last year; diluted EPS $0.51 versus $0.43.
- October 30, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 18, 2026Quarterly results 8-K/A
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $20.5M versus the same quarter last year; diluted EPS $0.41 versus $0.45.
- July 31, 2026Other event 8-K
- July 28, 2026Passive stake (5% or more) SCHEDULE 13G
- June 24, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 13% to $22M versus the same quarter last year; diluted EPS $0.45 versus $0.37.
What is IRMD worth? A DCF from its reported cash flow
Insider trades
What the people running Iradimed Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $122.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | Kiani Joe EDirector | Exercised options | 698 | - |
| September 3, 2026 | Allen Monty KDirector | Sold | 1,014 | $87.7K |
| September 3, 2026 | Allen Monty KDirector | Sold | 405 | $35K |
| June 20, 2026 | Glenn JohnCFO | Exercised options | 5,796 | - |
| June 20, 2026 | Glenn JohnCFO | Shares withheld for tax | 2,319 | $213.8K |
| June 4, 2026 | Scharen-Guivel Hilda FrederiqueDirector | Sold | 1,766 | $167.8K |
| June 4, 2026 | Scharen-Guivel Hilda FrederiqueDirector | Sold | 1,234 | $117.2K |
| June 1, 2026 | Susi Roger E.CEO, President, Chairman, Director, 10% owner | Soldpre-planned (10b5-1), indirect | 400 | $35.5K |
Who owns IRMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Roger E. Susi13G, passive with 4 related filers | 34.8% | May 14, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 2,230,648 shares in total, about $191.7M at the last price.
| Holder | Shares |
|---|---|
| Susi Roger E.CEO, President, Chairman, Director, 10% owner | 2,162,5002,162,500 held indirectly |
| Hawkins James BDirector | 29,647 |
| Allen Monty KDirector | 19,581 |
| Glenn JohnCFO | 11,937 |
| Scharen-Guivel Hilda FrederiqueDirector | 5,598 |
| Kiani Joe EDirector | 698 |
| Chiprin JeffChief Commercial Officer | 687 |
Questions about IRMD
What does Iradimed Corp do?
Iradimed Corp is a company in the Health care sector, listed on NASDAQ as IRMD. Its shares trade on NASDAQ under the ticker IRMD.
What is Iradimed Corp's net worth?
Iradimed Corp has a market value (market cap) of $1.1B at the latest share price, and shareholders' equity of $106.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Iradimed Corp profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $24M on revenue of $89.3M, a net margin of 26.8%.
How much revenue does Iradimed Corp make?
Over the twelve months to September 30, 2026 Iradimed Corp reported revenue of $89.3M. That is 11.0% more than a year earlier.
When did Iradimed Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 30, 2026. It covers the period to September 30, 2026.
When is Iradimed Corp's next earnings report?
Iradimed Corp's next report is expected around February 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IRMD with
Follow IRMD
Get an email when Iradimed Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Iradimed Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.